



INFORMATION DISCLOSURE STATEMENT

Applicant : Goddard, et al.
App. No : 10/063,712
Filed : May 8, 2002
For : SECRETED AND TRANSMEMBRANE
POLYPEPTIDES AND NUCLEIC ACIDS
ENCODING THE SAME
Examiner : Kaufman, Claire M.
Art Unit : 1646

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

August 5, 2005

(Date)

AnneMarie Kaiser, Reg. No. 37,649

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 9 references to be considered by the Examiner. Also enclosed are 17 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

08/09/2005 CNGUYEN2 00000011 10063712

04 FC:1806

180.00 OP

Dated: August 5, 2005

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

By: AnneMarie Kaiser

AnneMarie Kaiser

Registration No. 37,649

Attorney of Record

Customer No. 30,313

(619) 235-8550

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Multiple sheets used when necessary) SHEET 1 OF 2	Application No.	10/063,712
	Filing Date	May 8, 2002
	First Named Inventor	Goddard, et al.
	Art Unit	1646
	Examiner	Kaufman, Claire M.
	Attorney Docket No.	GNE.3230R1C143

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	4,894,225	01-16-1990	Zimmerman	
	2	4,963,354	10-16-1990	Shepard, et al.	
	3	4,980,160	12-25-1990	Goldberg, et al.	
	4	5,059,530	10-22-1991	Oshima, et al.	
	5	5,215,743	06-01-1993	Singh, et al.	
	6	5,436,154	07-25-1995	Barbanti, et al.	
	7	5,656,272	08-12-1997	Le, et al.	
	8	5,942,417	08-24-1999	Ni, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	9	CARSWELL, et al. 1975. An endotoxin-induced serum factor that causes necrosis of tumors. <i>Proc. Natl. Acad. Sci. USA</i> , 72(9):3666-3670.	
	10	EIGLER, et al. 1997. Taming TNF: Strategies to restrain this proinflammatory cytokine. <i>Immunology Today</i> , 18(10):487-492.	
	11	GenBank Accession No. AL158821	
	12	GOEDDEL, et al. 1986. Tumor necrosis factors: Gene structure and biological activities. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , Vol. LI. pp. 597-609.	
	13	HALLAHAN, et al. 1995. Spatial and temporal control of gene therapy using ionizing radiation. <i>Nature Medicine</i> , 1(8):786-791.	

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Multiple sheets used when necessary)	Application No.	10/063,712
	Filing Date	May 8, 2002
	First Named Inventor	Goddard, et al.
	Art Unit	1646
	Examiner	Kaufman, Claire M.
SHEET 2 OF 2	Attorney Docket No.	GNE.3230R1C143

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	14	NETA, et al. 1988. Interdependence of the radioprotective effects of human recombinant interleukin 1 α , tumor necrosis factor α , granulocyte colony-stimulating factor, and murine recombinant granulocyte-macrophage colony-stimulating factor. <i>The Journal of Immunology</i> , 140(1):108-111.	
	15	PALEOLOG, E. 1997. Target effector role of vascular endothelium in the inflammatory response: Insights from the clinical trial of anti-TNF α antibody in rheumatoid arthritis. <i>J. Clin. Pathol.: Mol. Pathol.</i> , 50:225-233.	
	16	PALEOLOG, E. 2003. The therapeutic potential of TNF- α blockade in rheumatoid arthritis. <i>Expert Opinion in Investig Drugs</i> , 12(7):1087-1095.	
	17	SUGANUMA, et al. 1999. Essential role of tumor necrosis factor α (TNF- α) in tumor promotion as revealed by TNF- α -deficient mice. <i>Cancer Research</i> , 59:4516-4518.	

1844696
080205

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.